{
    "nctId": "NCT02175186",
    "officialTitle": "Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention",
    "inclusionCriteria": "* Age between 20 and 80 years\n* Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks\n* Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy\n* mild gastrointestinal symptom\n* Creatinen in blood \u2264 3mg/dl\n* BUN \u2264 50mg/dl\n* Birilubin \u2264 3mg/dl\n* AST and ALT \u2264 80U/L\n* Must have minimum age of 20 Years\n* Must have maximum age of 80 Years",
    "exclusionCriteria": "* Pregnant or breast feeding\n* History of Stomach or esophagus surgery\n* Peptic ulcer or reflux esophagitis\n* Zollinger-Ellison syndrome or primary esophageal motility disorders\n* Malignant tumor\n* Bleeding tendency or coagulopathy\n* Contraindication of ALBIS\n* Long term use of aspirin or P2Y12 receptor antagonist within 1month\n* Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed)\n* Terminal patient"
}